Management

Michael joined Nykode Therapeutics in 2017. He is a broadly anchored pharmaceutical professional with extensive experience, from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas. His career history includes specialist and managerial roles at Takeda and Nycomed. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS).

Agnete is a co-founder of Nykode Therapeutics and served as Chief Scientific Officer from 2007-2021, leading our scientific strategy. Her previous employers include Affitech AS and Medinnova AS. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. Agnete holds an MSc and a Ph.D. from the Institute of Immunology, Rikshospitalet Medical Center in Oslo, where she designed and developed the first Vaccibody™ vaccine molecules. She received the King’s Gold Medal of Merit for her Ph.D. thesis describing vaccibodies.

With a long career in the field of finance, Harald joined Nykode Therapeutics in 2021 as CFO. Most recently, he was CFO at Flex LNG, a company owning and operating LNG carriers and listed on both the New York and Oslo Stock Exchanges. Previously, he was CFO in SFL Corporation Limited, a leading international ship-owning company listed on the NYSE. Harald also holds a MSc in Shipping, Trade and Finance from CASS Business School and a MSc in Marine Engineering and Naval Architecture from the Norwegian University of Science and Technology.

Mikkel joined Nykode Therapeutics in 2021. He has long experience in drug discovery and development within the areas of oncology, immuno-oncology and infectious diseases. His previous roles include Head of Biologics Drug Design at Servier and CSO of Symphogen, where he has also held the positions VP of Antibody Discovery and Research and Director of Cancer Biology and Immunology. Before that, Mikkel was leader of the receptor tyrosine kinase group at the Department of Radiation Biology at the Copenhagen University Hospital. Mikkel has also authored over 40 peer-reviewed publications.

Mette joined Nykode Therapeutics in 2017. Her professional experience spans CMC, including drug development through all clinical stages from early research to NDA/MAA filings. This work covers regulatory filings within both the antimicrobial and immune oncology programs, as well as diagnostic imaging. Mette’s career includes roles at Lytix Biopharma, Nycomed Pharma, Amersham Health and GE Healthcare. She holds a Ph.D. in peptide chemistry from the University of Oslo.

Siri joined Nykode Therapeutics as CMO in 2020, bringing her broad experience in clinical development and translational research. Furthermore, she has extensive experience in scientific and medical affairs covering relevant tumor areas, R&D and general management of cancer drug development, as well as product launches and life cycle management for several oncology products. Her past career includes roles with Oslo University Hospital (Radiumhospitalet), one of the premier oncology hospitals in Europe, as well as Novartis and AstraZeneca. Siri is a medical doctor and a certified clinical specialist in oncology.

Elise joined Nykode Therapeutics in 2021 as Chief Human Resources Officer. She has extensive experience with HR and organizational development in the Global Pharmaceutical and Medtech industry, her prior position being at Novartis in Norway as Head of People & Organization. Elise has since 2019 acted as Leader of the Education Committee in The Life Science Cluster at the Oslo Science Park, enabling collaboration and partnerships with several academic organizations (UIO, OsloMet, BI, NMBU), with a focus on designing education programmes based on the industry’s future need of competencies and innovation capabilities. Elise holds a bachelor of Management from BI Norwegian Business School and is currently finalizing an Executive Master of Management program specializing in Human Resources Management and Employment law.

Caspar joined Nykode Therapeutics in 2018, serving as Director of Business Development until 2021 when he took his current role. His professional experience spans from business development and strategy in Novozymes A/S to being an independent consultant to biotech companies. His roles and responsibilities have included diverse transactions within business development, fundraising and mergers & acquisitions. Caspar holds a MSc in Management from University of Surrey and a Bsc (Hons.) in Chemistry with Biological Chemistry from the University of St Andrews.

Katrine joined Nykode Therapeutics in 2020. She has extensive experience with leading global drug development projects of biologics and small molecules. Her work has covered early research to late-stage development in areas including immunology, neurology, dermatology and metabolic diseases. Her past positions include roles at LEO Pharma, Agilent, Takeda and Nycomed. Katrine holds a MSc in Pharmacy from the University of Copenhagen and a Master in Medical Business Strategy from the Copenhagen Business School.

Peter Fatum joined Nykode Therapeutics in 2021. He is a senior quality manager with broad experience within quality management across GxPs, covering both investigational and commercial products. He has 25 years of experience from the pharma & medtech industry covering R&D, Product Support and QA/QC. Most recently, he held the role of Head of Global GxP Compliance & Quality Systems in Sobi (Swedish Orphan Biovitrum AB), a global biopharmaceutical company working with rare diseases. Past employments includes senior Global QA roles in ALK and Radiometer. He holds a MSc in Chemistry and Environmental Biology from Roskilde University in Denmark.